Xenetic Biosciences Q1 2025: net loss $0.9M, revenue $0.6M (+16%), cash $5.2M

Xenetic Biosciences, Inc.

2025-Q1 EPS reported -$0.59 vs consensus -$0.73 ▲ beat (+19.7%)

Net loss of ~$0.9M for Q1 2025; revenue increased 16.1% to ~$0.6M from $0.5M in Q1 2024.
Total operating costs decreased 13.7% to ~$1.5M, primarily due to lower personnel costs after CEO/CSO departures in mid-2024.
Cash position of $5.2M at quarter end; no guidance or dividend changes.
Advancing DNase I platform; collaboration with PeriNess for exploratory studies in osteosarcoma, Ewing sarcoma, and pancreatic carcinoma.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.